Posted by Michael Wonder on 31 Mar 2022
Outlook Therapeutics submits biologics license application to the U.S. Food and Drug Administration for ONS-5010 as a treatment for wet AMD
31 March 2022 - ONS-5010 / LYTENAVA (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivity.
Outlook Therapeutics today announced it has submitted its biologics license application to the U.S. FDA for ONS-5010, an investigational therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg), for the treatment of wet age-related macular degeneration.
